Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 18;16(6):1197.
doi: 10.3390/cancers16061197.

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions

Rugile Pikturniene  1   2 , Alvydas Cesas  2 , Sonata Jarmalaite  1   3 , Arturas Razbadauskas  2   4 , Vincas Urbonas  3
Affiliations
Review

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions

Rugile Pikturniene et al. Cancers (Basel). .

Abstract

Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, present limitations, prompting exploration of alternative biomarkers. This review comprehensively explores the role of circulating tumor DNA (ctDNA) in advanced melanoma, covering technical aspects, detection methods, and its prognostic and predictive value. Recent findings underscore ctDNA's potential applications and implications in clinical practice. This review emphasizes the need for precise and dynamic biomarkers in melanoma care, positioning ctDNA as a promising blood-based tool for prognosis, treatment response, and resistance mechanisms. The technical nuances of ctDNA detection, association with melanoma mutations, and its role in guiding therapeutic decisions for immunotherapy and targeted therapy underscore its multifaceted utility, marking a paradigm shift in clinical decision-making and offering a promising trajectory for personalized and informed care in advanced melanoma.

Keywords: biomarkers; ctDNA; immunotherapy; melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Potential clinical utility of ctDNA.
Figure 2
Figure 2
ctDNA in melanoma management.
See this image and copyright information in PMC

References

    1. Arnold M., Singh D., Laversanne M., Vignat J., Vaccarella S., Meheus F., Cust A.E., Vries E.D., Whiteman D.C., Bray F. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495–503. doi: 10.1001/jamadermatol.2022.0160. - DOI - PMC - PubMed
    1. Singh S.R.K., Malapati S.J., Kumar R., Willner C., Wang D. NCDB Analysis of Melanoma 2004–2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval. Cancers. 2021;13:1455. doi: 10.3390/cancers13061455. - DOI - PMC - PubMed
    1. Adams R., Coumbe J.E.M., Coumbe B.G.T., Thomas J., Willsmore Z., Dimitrievska M., Yasuzawa-Parker M., Hoyle M., Ingar S., Geh J.L.C., et al. BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev. Clin. Immunol. 2022;18:347–362. doi: 10.1080/1744666X.2022.2044796. - DOI - PubMed
    1. Aide N., Iravani A., Prigent K., Kottler D., Alipour R., Hicks R.J. PET/CT variants and pitfalls in malignant melanoma. Cancer Imaging. 2022;22:3. doi: 10.1186/s40644-021-00440-4. - DOI - PMC - PubMed
    1. Patel M., Eckburg A., Gantiwala S., Hart Z., Dein J., Lam K., Puri N. Resistance to molecularly targeted therapies in melanoma. Cancers. 2021;13:1115. doi: 10.3390/cancers13051115. - DOI - PMC - PubMed

LinkOut - more resources